Among them, the circulating autoantibodies against coatomer protein complex subunit epsilon, which can be a biomarker of CAD and stroke risk in patients with OSA [19], and bone morphogenetic protein antagonist neuroblastoma suppressor of tumorigenicity which can be a potential biomarker of cardiovascular risk in patients with OSA were identified [16]. The gene discussed is COPE; the disease is obstructive sleep apnea syndrome.